

Global Cancer/Tumor Profiling Market Analysis and Forecast 2022 by Size, Share and Growth Rate

OrbisResearch.com has published new research report on "Cancer/Tumor Profiling-Global Market Outlook (2016-2022)" to its database.

DALLAS, TEXAS, U.S.A., February 23, 2017 /EINPresswire.com/ -- According to Statistics MRC, the [Global Cancer/Tumor Profiling Market](#) is expected to grow from \$23.04 billion in 2015 to reach \$78.69 billion by 2022 with a CAGR of 19.2%. Increasing cases of cancer and the need for therapy are the major factors influencing the market growth. Moreover, high investments in R&D, technological developments, and demand for safer medicines are the factors fostering the market growth. However, low awareness among clinicians about options and potential of cancer profiling are the major challenges for this market.



Request a sample of the report:
<http://www.orbisresearch.com/contacts/request-sample/184907>

By application, personalized medicines segment leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth is attributed by unique characteristics of this segment in examining and prognosis of cancer disease. North America commands the market due to the presence of leading cancer profiling industry leaders. Asia Pacific is expected to witness huge growth due to raising incidence of cancer in this region.

Some of the key players in global Cancer/Tumor profiling market include Agendia Nv, Biotheranostics, Boreal Genomics, Inc., Caris Life Sciences, Genomic Health, Inc., Illumina, Inc., Life Technologies Corporation, Nanostring Technologies, Neogenomics Laboratories, Oncopath Laboratory, Oxford Gene Technology Ltd, Precision Therapeutics, Inc., Proteome Sciences Plc, Rational Therapeutics, and Ribomed Biotechnologies.

Buy the report@<http://www.orbisresearch.com/contact/purchase/184907>

Applications Covered:
Biomarker Discovery
Diagnostics
Personalized Medicine
Prognosis
Research Applications

Technologies Covered:

Fluorescence/Chromogenic In Situ Hybridization

Immunohistochemistry

Microarray

Next-Generation Sequencing

Quantitative PCR

Check for the discount:<http://www.orbisresearch.com/contacts/discount/184907>

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

France

Italy

UK

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

Rest of Asia Pacific

Rest of the World

Middle East

Brazil

Argentina

South Africa

Egypt

What our report offers:

- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete

information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Hector Costello
Orbis Research
+1 (214) 884-6817
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.